



[REDACTED]

Mr. Thomas Lönngren
Executive Director
SME Office
EMA
7 Westferry Circus
Canary Wharf,
London, E14 4HB

RE: Withdrawal of *Contusogene ladenovec*, 2.2×10^{12} viral particles suspension
for injection - EMA/H/C/001041

Dear Mr. Lönngren,

Gendux Molecular Limited has made the decision to withdraw the Marketing Authorisation Application for *Contusogene ladenovec*, 2.2×10^{12} viral particles suspension for injection, which was intended to be used for the treatment of squamous cell carcinoma in head and neck cancer.

The withdrawal is based on the extreme financial difficulty being faced by Gendux Molecular Limited's parent company, Introgen Therapeutics, Inc., which recently filed for Chapter 11 bankruptcy in the US courts system. Introgen Therapeutics, Inc.'s financial state prohibits it from funding further activities related to this MAA.

We reserve the right to make further submissions at a future date for this or other therapeutics indication(s).

We permit the text of this letter to be published on the EMA website.

Sincerely,

[REDACTED]

[REDACTED]